---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-21-021239"
form_type: "8-K"
ticker: "AUPH"
cik: "0001600620"
company_name: "Aurinia Pharmaceuticals Inc."
filed_at: "2021-11-03T23:59:59+00:00"
generated_at: "2026-06-28T14:02:51.659310+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Aurinia Q3 revenue $14.7M (+122% QoQ); net loss $50.3M; LUPKYNIS PSF conversion >68%

## Summary
- Net revenue $14.7M vs $29K in Q3 2020; net loss $50.3M ($0.39 per share) vs $42.1M loss a year ago.
- Cash and investments $286.4M; 2021 revenue guidance maintained at $40-50M.
- LUPKYNIS PSFs totaled 412 in Q3; cumulative >1,265; conversion rate improved to >68% from 50% in Q2.
- Payer coverage confirmed for 87% of total lives; two preclinical assets AUR200 and AUR300 added.
- AURORA 2 final results expected by end of 2021; Swiss MAA filed; EMA decision anticipated Q3 2022.

## SEC filing metadata
- accession: 0001628280-21-021239
- form_type: 8-K
- ticker: AUPH
- cik: 0001600620
- company_name: Aurinia Pharmaceuticals Inc.
- filed_at: 2021-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1600620/000162828021021239/0001628280-21-021239-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1600620/000162828021021239/auph-20211103.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-21-021239
- JSON: https://secwatch.observer/filing/0001628280-21-021239.json
- Plain text: https://secwatch.observer/filing/0001628280-21-021239.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.